Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)

Authors:

Abstract
No abstract available
Funding Information
  • Merck Sharp and Dohme United Kingdom

This publication has 26 references indexed in Scilit: